Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
Eudocia Q. Lee(Brigham and Women's Hospital), Patrick Y. Wen(Dana-Farber Cancer Institute), Glenn J. Lesser(Virginia Commonwealth University), Stuart A. Grossman(Johns Hopkins University), Martin J. van den Bent(Erasmus MC Cancer Institute), Frank S. Lieberman(University of Pittsburgh), Michael Weller(University Hospital of Zurich), Evanthia Galanis(Mayo Clinic in Arizona), Joohee Sul(United States Food and Drug Administration), Roy E. Strowd(Wake Forest University), Solmaz Sahebjam(Johns Hopkins University), Tobias Walbert(Henry Ford Health System), Jian Campian, Manmeet S. Ahluwalia(Baptist Hospital of Miami), Minesh P. Mehta(Columbia University), David A. Reardon(Dana-Farber Cancer Institute), Karisa C. Schreck(Johns Hopkins University), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Burt Nabors(University of Alabama at Birmingham), Matthias Holdhoff(Johns Hopkins University), Michael A. Vogelbaum(Moffitt Cancer Center), Marta Peñas-Prado(National Institutes of Health), Susan M. Chang(University of San Francisco), Stephen Bagley(University of Pennsylvania)
Cited by 40
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k